A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Status:
RECRUITING
Trial end date:
2028-11-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).